PracticeVideosBlogFlashcardsEspañol
All Practice Exams

100+ Free PRC Ocular Pharmacologist Practice Questions

Pass your Special Certification Examination in Ocular Pharmacology (Ocular Pharmacologist) exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
October 2025: 88.9% (24/27 passed) Pass Rate
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Philippines PRC Health Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Board Licensure Examination for Psychologists (BLEPP), Philippines

Practice Questions

Board Licensure Examination for Psychometricians (BLEPM), Philippines

Practice Questions

Guidance Counselor Licensure Examination (GCLE), Philippines

Practice Questions

Nutritionist-Dietitian Licensure Examination

Practice Questions

Philippine Dentist Licensure Examination

Practice Questions

Philippine Medical Technologists Licensure Examination

Practice Questions
2026 Statistics

Key Facts: PRC Ocular Pharmacologist Exam

5

DPA agents authorized under RA 8050 Section 31

Republic Act No. 8050, Section 31 and Board of Optometry regulations

₱1,500

published special certification exam fee

PRC published examination requirements

88.9%

October 2025 pass rate (24 of 27 passed)

PRC examination results

75%

minimum general weighted average required to pass

PRC Board of Optometry passing standards under RA 8050

7

topic areas in this practice bank

PRC Board of Optometry curriculum for Ocular Pharmacology

100

original practice questions in this bank

Open Exam Prep practice bank

The PRC Ocular Pharmacologist Special Certification Examination is a post-licensure computer-based test for licensed Philippine Optometrists under RA 8050 Section 31. It covers general pharmacology, ocular anatomy and physiology, drug classes (miotics, mydriatics, cycloplegics, anti-glaucoma agents, anti-infectives, anti-inflammatories, anti-VEGF agents), and optometry law and DPA regulations. Passing authorizes use of specific Diagnostic Pharmaceutical Agents. The exam fee is ₱1,500 and the October 2025 cohort had an 88.9% pass rate.

Sample PRC Ocular Pharmacologist Practice Questions

Try these sample questions to test your PRC Ocular Pharmacologist exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which route of drug administration provides the highest initial drug concentration in the precorneal area and is the most common method used for topical ocular pharmacotherapy?
A.Topical instillation of eye drops
B.Systemic oral administration
C.Intravitreal injection
D.Subconjunctival injection
Explanation: Topical instillation of eye drops delivers drug directly to the precorneal area, achieving high local concentrations with minimal systemic absorption. It is by far the most common and convenient route for anterior segment ocular pharmacotherapy.
2Nasolacrimal drainage of a topically applied ophthalmic drug is a significant pharmacokinetic concern because it can lead to which consequence?
A.Systemic absorption through nasal mucosa causing unwanted systemic side effects
B.Improved corneal drug penetration
C.Enhanced retinal drug delivery
D.Prolonged drug retention in the tear film
Explanation: After topical instillation, excess drug drains through the nasolacrimal duct to the nasal mucosa, where it can be absorbed systemically. This is a significant concern for drugs such as timolol, which can cause bradycardia and bronchospasm via nasal mucosal absorption.
3The concept of a drug's half-life is most useful clinically for determining which dosing parameter?
A.How frequently the drug must be administered to maintain therapeutic concentration
B.The maximum concentration the drug can achieve in the eye
C.Whether a drug penetrates the corneal epithelium
D.The drug's mechanism of receptor binding
Explanation: Half-life reflects the time needed for plasma (or tissue) drug concentration to decrease by 50%. It is used to determine dosing frequency — drugs with shorter half-lives generally require more frequent administration to maintain therapeutic levels.
4A drug that binds to a receptor and produces a maximal biological response is classified as which type of drug?
A.Full agonist
B.Partial agonist
C.Competitive antagonist
D.Inverse agonist
Explanation: A full agonist binds to a receptor and produces a maximal biological response (100% efficacy). This distinguishes it from partial agonists, which bind but produce a submaximal response regardless of concentration.
5Drug metabolism in the liver most commonly converts lipophilic drugs to more hydrophilic metabolites. What is the primary purpose of this biotransformation?
A.To facilitate renal excretion of the drug
B.To increase the drug's corneal penetration
C.To enhance the drug's binding to plasma proteins
D.To increase the drug's ability to cross the blood-brain barrier
Explanation: Phase I and Phase II hepatic metabolism convert lipophilic drugs to more polar, water-soluble metabolites, making them more easily filtered and excreted by the kidneys. This is the primary route of drug elimination for most systemic drugs.
6Which physicochemical property of a drug molecule most facilitates its passive diffusion across the intact corneal epithelium?
A.Adequate lipophilicity (fat-solubility)
B.High molecular weight above 1000 Da
C.Strongly ionized (charged) at physiological pH
D.Hydrophilicity
Explanation: The corneal epithelium is a lipid membrane barrier, so drugs must have sufficient lipophilicity to passively diffuse through it. However, the corneal stroma is hydrophilic, so ideal ophthalmic drugs are amphoteric — balancing lipophilicity and hydrophilicity.
7An adverse drug reaction occurs when a patient taking two medications simultaneously experiences a greater-than-expected pharmacological effect from one drug due to the second drug inhibiting the first drug's metabolism. This is an example of which type of drug interaction?
A.Pharmacokinetic drug interaction (metabolic inhibition)
B.Pharmacodynamic synergism
C.Physicochemical incompatibility
D.Pharmacodynamic antagonism
Explanation: Inhibition of cytochrome P450 enzymes by one drug reduces the metabolism of a co-administered drug, leading to elevated plasma concentrations and enhanced (sometimes toxic) effects. This is a classic pharmacokinetic drug-drug interaction.
8Benzalkonium chloride (BAC) is the most commonly used preservative in topical ophthalmic preparations. Which ocular structure is most susceptible to chronic toxicity from BAC-preserved drops?
A.Corneal epithelium
B.Vitreous humor
C.Optic nerve
D.Crystalline lens
Explanation: Benzalkonium chloride is a quaternary ammonium detergent that disrupts cell membranes. Chronic exposure can cause corneal epithelial toxicity, punctate keratopathy, and goblet cell loss. Patients using multiple preserved drops (e.g., for glaucoma) are particularly at risk.
9The therapeutic window of a drug refers to which concentration range?
A.The range between the minimum effective concentration and the minimum toxic concentration
B.The concentration at which the drug is maximally metabolized
C.The range of doses used in pediatric patients only
D.The pH range in which the drug remains stable
Explanation: The therapeutic window (or therapeutic index) defines the range of drug concentrations that achieve a therapeutic effect without causing unacceptable toxicity. A narrow therapeutic window means greater difficulty in dosing safely.
10When comparing two ophthalmic drugs at equipotent doses, the drug with lower relative toxicity is said to have a higher what?
A.Therapeutic index
B.Bioavailability
C.First-pass effect
D.Volume of distribution
Explanation: The therapeutic index (TI) is the ratio of the median toxic dose (TD50) to the median effective dose (ED50). A higher TI indicates a greater safety margin — the drug can achieve therapeutic effects at doses much lower than those causing toxicity.

About the PRC Ocular Pharmacologist Exam

The Special Certification Examination in Ocular Pharmacology, also known as the PRC Ocular Pharmacologist certification, is administered by the PRC Board of Optometry under Section 31 of Republic Act No. 8050 (Revised Optometry Law of 1995). Passing this exam authorizes licensed Filipino Optometrists to use specific Diagnostic Pharmaceutical Agents (DPA) including phenylephrine 2.5%, tropicamide 0.5%, proparacaine 0.5%, oxybuprocaine HCl 0.4%, and fluorescein strips in their optometric practice.

Assessment

Computer-based multiple-choice special certification examination covering General Pharmacology (20%), Ocular Anatomy and Physiology (15%), Miotics/Mydriatics/Cycloplegics (15%), Anti-Glaucoma Agents (15%), Anti-infectives & Anti-inflammatories (15%), Anti-VEGF & Ocular Pharmacotherapy (10%), and Optometry Law, Ethics & DPA Regulations (10%).

Time Limit

Single-day computer-based examination; exact duration per administration set by PRC Board of Optometry

Passing Score

General weighted average of at least 75%, with no subject rating below 50%, consistent with RA 8050 standards

Exam Fee

₱1,500.00 (Professional Regulation Commission (PRC) / Professional Regulatory Board of Optometry)

PRC Ocular Pharmacologist Exam Content Outline

20%

General Pharmacology

Pharmacokinetics (absorption, distribution, metabolism, excretion), pharmacodynamics, receptor theory, agonists and antagonists, dose-response relationships, drug-drug interactions, adverse drug reactions, ocular drug delivery routes, and biochemical principles relevant to ocular pharmacotherapy.

15%

Ocular Anatomy and Physiology

Anterior segment (cornea, conjunctiva, iris, ciliary body, lens), posterior segment (retina, choroid, vitreous), tear film physiology, aqueous humor dynamics and outflow, intraocular pressure regulation, blood-ocular barrier (blood-aqueous and blood-retinal barriers), and ocular pharmacokinetics affecting drug penetration and distribution.

15%

Miotics and Mydriatics/Cycloplegics

Cholinergic miotics (pilocarpine, carbachol, echothiophate), anticholinergic cycloplegics and mydriatics (tropicamide, cyclopentolate, atropine, scopolamine, homatropine), sympathomimetic mydriatics (phenylephrine), clinical uses in refraction, fundoscopy, and glaucoma, with indications, contraindications, and systemic side effects.

15%

Anti-Glaucoma Agents

Prostaglandin analogs (latanoprost, travoprost, bimatoprost, tafluprost), topical beta-blockers (timolol, betaxolol, levobunolol), alpha-2 adrenergic agonists (brimonidine, apraclonidine), topical and systemic carbonic anhydrase inhibitors (dorzolamide, brinzolamide, acetazolamide, methazolamide), cholinergic agents for glaucoma, Rho-kinase inhibitors (netarsudil), combination products, mechanisms of action, and systemic contraindications.

15%

Ocular Anti-infectives and Anti-inflammatories

Topical antibiotics (fluoroquinolones: ciprofloxacin, ofloxacin, moxifloxacin; aminoglycosides: tobramycin, gentamicin; macrolides: azithromycin; chloramphenicol), antifungals (natamycin, voriconazole, amphotericin B), antivirals (acyclovir, ganciclovir, trifluridine), corticosteroids (prednisolone, dexamethasone, loteprednol, fluorometholone), topical NSAIDs (ketorolac, diclofenac, nepafenac, bromfenac), topical antihistamines and mast cell stabilizers (olopatadine, ketotifen, cromolyn).

10%

Anti-VEGF Agents and Ocular Pharmacotherapy

Anti-VEGF biologics for neovascular AMD, diabetic macular edema, and retinal vein occlusion (ranibizumab, bevacizumab, aflibercept, brolucizumab, faricimab); intravitreal drug delivery principles; ocular lubricants, tear substitutes, and punctal plugs; retinal agents and surgical adjuncts (mitomycin C, 5-fluorouracil); principles of preservatives and ocular toxicity.

10%

Optometry Law, Ethics, and DPA Regulations

Republic Act No. 8050 (Revised Optometry Law of 1995), Section 31 provisions on Diagnostic Pharmaceutical Agents, the five DPA-authorized agents under RA 8050 (phenylephrine 2.5%, tropicamide 0.5%, proparacaine 0.5%, oxybuprocaine HCl 0.4%, fluorescein strips), PRC Board of Optometry issuances, Code of Ethics for Filipino Optometrists, prescription writing guidelines, professional responsibilities and liability of the Ocular Pharmacologist, and related healthcare laws.

How to Pass the PRC Ocular Pharmacologist Exam

What You Need to Know

  • Passing score: General weighted average of at least 75%, with no subject rating below 50%, consistent with RA 8050 standards
  • Assessment: Computer-based multiple-choice special certification examination covering General Pharmacology (20%), Ocular Anatomy and Physiology (15%), Miotics/Mydriatics/Cycloplegics (15%), Anti-Glaucoma Agents (15%), Anti-infectives & Anti-inflammatories (15%), Anti-VEGF & Ocular Pharmacotherapy (10%), and Optometry Law, Ethics & DPA Regulations (10%).
  • Time limit: Single-day computer-based examination; exact duration per administration set by PRC Board of Optometry
  • Exam fee: ₱1,500.00

Keys to Passing

  • Complete 500+ practice questions
  • Score 80%+ consistently before scheduling
  • Focus on highest-weighted sections
  • Use our AI tutor for tough concepts

PRC Ocular Pharmacologist Study Tips from Top Performers

1Memorize the five DPA-authorized agents under RA 8050 Section 31 (phenylephrine 2.5%, tropicamide 0.5%, proparacaine 0.5%, oxybuprocaine HCl 0.4%, fluorescein strips) — these are high-yield for the law and pharmacology sections.
2Understand drug mechanisms: miotics work on cholinergic receptors to constrict the pupil; mydriatics block muscarinic receptors (anticholinergics) or stimulate alpha receptors (sympathomimetics).
3For anti-glaucoma agents, organize by mechanism: prostaglandins increase uveoscleral outflow; beta-blockers and CAIs decrease aqueous humor production; alpha-2 agonists do both; pilocarpine increases trabecular outflow.
4Know systemic side effects of anti-glaucoma agents: timolol is contraindicated in asthma and bradycardia; systemic acetazolamide causes electrolyte disturbances and is contraindicated in sulfa allergy.
5For anti-infectives, remember fluoroquinolones as first-line topical antibiotics for bacterial keratitis; antivirals like acyclovir for herpes simplex keratitis; natamycin for fungal keratitis.
6Study the blood-aqueous and blood-retinal barriers to understand why intravitreal anti-VEGF injections are needed for posterior segment disease rather than topical drugs.
7Review RA 8050 thoroughly, especially Section 31. Know that only the Board of Optometry with DOH and BFAD approval can add agents to the DPA list beyond the five listed.

Frequently Asked Questions

What is the PRC Ocular Pharmacologist examination?

It is the Special Certification Examination in Ocular Pharmacology administered by the PRC Board of Optometry under Section 31 of Republic Act No. 8050. Passing authorizes licensed Filipino Optometrists to use specified Diagnostic Pharmaceutical Agents (DPA) in their practice.

Which Diagnostic Pharmaceutical Agents (DPA) are authorized under RA 8050?

Under RA 8050 and Board of Optometry regulations, the authorized DPA are: phenylephrine 2.5% ophthalmic drops, tropicamide 0.5% ophthalmic drops, proparacaine 0.5% ophthalmic drops, oxybuprocaine HCl 0.4% ophthalmic drops, and fluorescein strips.

Who is eligible to take the PRC Ocular Pharmacologist examination?

Licensed Filipino Optometrists (OD) who have completed the required Special Pharmacology Course prescribed by the Board of Optometry and CHED. Applicants must hold a valid PRC Optometrist Professional Identification Card and meet documentary requirements.

How much is the PRC Ocular Pharmacologist exam fee?

The examination fee is ₱1,500.00 per PRC publications for the Special Certification Examination.

What is the passing score?

A general weighted average of at least 75%, with no subject rating below 50%, consistent with PRC Board of Optometry standards under RA 8050.

What is the pass rate?

Pass rates vary significantly by cohort. October 2025: 24 of 27 passed (88.9%); October 2023: 1 of 2 passed; July 2012: 18 of 19 passed.

Are these copied PRC board questions?

No. These are original practice questions written from the PRC Board of Optometry curriculum, RA 8050, and standard ocular pharmacology and pharmacotherapy concepts. They are not copied from official PRC examinations or private review centers.

What topics are covered in the exam?

The examination covers: General Pharmacology, Ocular Anatomy and Physiology, Miotics/Mydriatics/Cycloplegics, Anti-Glaucoma Agents, Ocular Anti-infectives and Anti-inflammatories, Anti-VEGF Agents and Ocular Pharmacotherapy, and Optometry Law/Ethics/DPA Regulations (RA 8050).